JP Morgan Chase
AARD

JP Morgan Chase’s Aardvark Therapeutics AARD Stock Holding History

JP Morgan Chase’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.1K Sell
6,617
-266
-4% -$2.76K ﹤0.01% 6484
2025
Q4 		$90.3K Buy
6,883
+4,567
+197% +$57K ﹤0.01% 5941
2025
Q3 		$30.8K Sell
2,316
-361
-13% -$4.07K ﹤0.01% 6381
2025
Q2 		$36.2K Sell
2,677
-423
-14% -$4.36K ﹤0.01% 6031
2025
Q1 		$23.3K Buy
+3,100
New +$34.8K ﹤0.01% 6106

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

JP Morgan Chase's AARD Position: Q1 2026 in Review

JP Morgan Chase reduced its Aardvark Therapeutics (AARD) stake by 3.9% in Q1 2026, selling an estimated $2.76K and leaving 6,617 shares worth $24.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6484.

JP Morgan Chase first reported a position in AARD in Q1 2025 and has held it in 5 quarters since. The position peaked at $90.3K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • JP Morgan Chase held 6,617 shares of Aardvark Therapeutics worth $24.1K as of Q1 2026.
  • JP Morgan Chase sold 266 Aardvark Therapeutics shares in Q1 2026, an estimated $2.76K.
  • Aardvark Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6484 holding.
  • JP Morgan Chase first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • JP Morgan Chase's Aardvark Therapeutics position peaked at $90.3K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.